Context Therapeutics (CNTX) Insider Trading & Ownership $0.81 +0.02 (+2.41%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.82 +0.01 (+1.11%) As of 02/21/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Context Therapeutics (NASDAQ:CNTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.04%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$77,169.74Number OfInsiders Selling(Last 3 Years)0 Get CNTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Context Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CNTX Insider Buying and Selling by Quarter Context Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/21/2023Martin A LehrCEOBuy5,823$0.84$4,891.32 2/13/2023Martin A LehrCEOBuy5,606$0.87$4,877.22 2/6/2023Martin A LehrCEOBuy5,040$0.97$4,888.80 1/30/2023Martin A LehrCEOBuy7,027$0.70$4,918.90 1/23/2023Martin A LehrCEOBuy6,839$0.72$4,924.08 1/17/2023Martin A LehrCEOBuy6,783$0.74$5,019.42 12/16/2022Jennifer Lynn Minai-AzaryCFOBuy25,000$0.74$18,500.00 12/9/2022Alex C LevitInsiderBuy6,000$0.85$5,100.00 8/19/2022Martin A LehrCEOBuy13,000$1.85$24,050.00 (Data available from 1/1/2013 forward) CNTX Insider Trading Activity - Frequently Asked Questions Who is on Context Therapeutics's Insider Roster? The list of insiders at Context Therapeutics includes Alex C Levit, Jennifer Lynn Minai-Azary, and Martin A Lehr. Learn more on insiders at CNTX. What percentage of Context Therapeutics stock is owned by insiders? 3.04% of Context Therapeutics stock is owned by insiders. Learn more on CNTX's insider holdings. Context Therapeutics Key ExecutivesMr. Martin A. Lehr (Age 40)Co-Founder, President, CEO & Director Compensation: $674.08kMs. Jennifer Minai-Azary (Age 46)CFO & Treasurer Compensation: $504.14kMr. Alex C. Levit Esq. (Age 45)Chief Legal Officer & Corporate Secretary Compensation: $483.83kMr. Christopher Beck M.B.A.Senior Vice President of Operations More Insider Trading Tools from MarketBeat Related Companies LFVN Insider Selling VYGR Insider Selling DSGN Insider Selling FDMT Insider Selling LFCR Insider Selling CCCC Insider Selling CRDF Insider Selling SLRN Insider Selling LRMR Insider Selling OCGN Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:CNTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
